FDA approves Pfizer's Tukysa regimen for front-line maintenance in HER2+ metastatic breast cancer
Bitget2026/10/07 16:57FDA cleared Pfizer’s Tukysa with trastuzumab, pertuzumab as front-line maintenance for unresectable locally advanced or metastatic HER2+ breast cancer. HER2CLIMB-05 showed median PFS of 24.9 months vs 16.3 months for placebo, hazard ratio 0.64. Label highlights higher hepatotoxicity risk; one fatal drug-induced liver injury reported in the trial. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007040182) on October 07, 2026, and is solely responsible for the information contained therein.
- FDA cleared Pfizer’s Tukysa with trastuzumab, pertuzumab as front-line maintenance for unresectable locally advanced or metastatic HER2+ breast cancer.
- HER2CLIMB-05 showed median PFS of 24.9 months vs 16.3 months for placebo, hazard ratio 0.64.
- Label highlights higher hepatotoxicity risk; one fatal drug-induced liver injury reported in the trial.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank Quarterly Preview: Net Interest-Bearing Debt Rises to 10.8 Trillion Yen
Nvidia plans a new round of investment in South Korean startups
Crypto prices
More
